ABSTRACT
AIM: To study effectiveness of the use of the anti-leukotriene drug montelukast in combination with inhalation glucocorticoid and long-acting beta-agonist in patients with bronchial asthma (BA) and cold-induced bronchial hyperactivity (CBHA) with a view to optimizing control of the disease. MATERIALS AND METHODS: We carried out an open comparative prospective study of patients with persistent BA in a cold season under conditions of real clinical practice. The patients were divided into 2 groups. Group 1 included patients with CBHA, group 2 consisted of subjects with constant bronchial reactivity in response to cold in the standard provocative test. The patients were followed up for 24 weeks. During the first 12 weeks of the treatment, the patients of group I were given sodium montelukast with budesonide/formoterol. In the next 12 weeks they received only budesonide/formoterol at the same dose. Patients of group 2 were treated with budesonide/formoterol during the entire study period. Efficacy of therapy was assessed by asthma control test (ACT). RESULTS: Control of BA in group 1 (20-25 scores in A CT) was achieved in 83% of the patients within the first 12 week period The result was comparable (87%) with that in group 2. Impairment of control (to 52%) was documented in group I during the last 12 weeks although it was preserved (20-25 scores) in group 2 (81%). CONCLUSION: The use of sodium montelukast in combination with budesonide/formoterol for the treatment of BA with CBHA in winter season ensured control of the disease in most patients during 12 weeks. Withdrawal of montelukast in the subsequent period leads to the loss of control and a rise in the frequency of exacerbation.
Subject(s)
Acetates/administration & dosage , Asthma/drug therapy , Bronchial Hyperreactivity/complications , Cold Temperature/adverse effects , Quinolines/administration & dosage , Administration, Inhalation , Adolescent , Adult , Anti-Asthmatic Agents/administration & dosage , Asthma/complications , Bronchial Hyperreactivity/drug therapy , Cyclopropanes , Female , Follow-Up Studies , Humans , Male , Middle Aged , Prospective Studies , Sulfides , Treatment Outcome , Young AdultABSTRACT
The results of the work on the development of an enzyme immunoassay (EIA) system for the determination of secretory IgA (S-IgA) are presented. A first, S-IgA was isolated from human colostrum and used as the basis for obtaining biologically active immunosorbent; then antibodies to S-IgA were isolated and the specific conjugate was obtained. The determination of S-IgA was carried out by the method of sandwich EIA. The newly developed EIA system permitted the determination of S-IgA only, giving no positive reactions with serum immunoglobulins. The data thus obtained make it possible to regard this assay system as specific, sensitive and suitable for further trials.
Subject(s)
Immunoglobulin A, Secretory/analysis , Antibody Specificity , Chromatography, Gel , Colostrum/immunology , Humans , Immunodiffusion , Immunoenzyme Techniques , Immunoglobulin A, Secretory/isolation & purificationABSTRACT
The problems of selecting the concentration of reagents with the aim of increasing the accuracy and sensitivity of reactions, as well as decreasing the consumption of reagents, are shown as exemplified by the antigen-antibody reaction of the first order. A new approach to the ELISA reaction is proposed, which makes it possible to present the totality of consecutive interactions of the reagents as block diagrams described by known mathematical expressions. The limitations of the linear dependence of the results of the reaction are shown, and the methodological recommendations for overcoming these limitations are given.
